NY AG Takes Up Pay-For-Delay Mantle With Teva Deal
Generic-drug makers Teva Pharmaceuticals USA Inc. and Ranbaxy Pharmaceuticals Inc. on Wednesday promised to put an end to an agreement that kept them from challenging each other's so-called first-filer exclusivity periods,...To view the full article, register now.
Already a subscriber? Click here to view full article